The Vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation

Federico Innocenti*, Kouros Owzar, Chen Jiang, Amy S. Etheridge, Raluca Gordân, Alexander B. Sibley, Flora Mulkey, Donna Niedzwiecki, Dylan Glubb, Nicole Neel, Mark S. Talamonti, David J. Bentrem, Eric Seiser, Jen Jen Yeh, Katherine Van Loon, Howard McLeod, Mark J. Ratain, Hedy L. Kindler, Alan P. Venook, Yusuke NakamuraMichiaki Kubo, Gloria M. Petersen, William R. Bamlet, Robert R. McWilliams

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Purpose Advanced pancreatic cancer is a highly refractory disease almost always associated with survival of little more than a year. New interventions based on novel targets are needed. We aim to identify new genetic determinants of overall survival (OS) in patients after treatment with gemcitabine using genome-wide screens of germline DNA. We aim also to support these findings with in vitro functional analysis. Patients and methods Genome-wide screens of germline DNA in two independent cohorts of pancreatic cancer patients (from the Cancer and Leukemia Group B (CALGB) 80303 and the Mayo Clinic) were used to select new genes associated with OS. The vitamin D receptor gene (VDR) was selected, and the interactions of genetic variation in VDR with circulating vitamin D levels and gemcitabine treatment were evaluated. Functional effects of common VDR variants were also evaluated in experimental assays in human cell lines. Results The rs2853564 variant in VDR was associated with OS in patients from both the Mayo Clinic (HR 0.81, 95% CI 0.70–0.94, p = 0.0059) and CALGB 80303 (HR 0.74, 0.63–0.87, p = 0.0002). rs2853564 interacted with high pre-treatment levels of 25-hydroxyvitamin D (25(OH)D, a measure of endogenous vitamin D) (p = 0.0079 for interaction) and with gemcitabine treatment (p = 0.024 for interaction) to confer increased OS. rs2853564 increased transcriptional activity in luciferase assays and reduced the binding of the IRF4 transcription factor. Conclusion Our findings propose VDR as a novel determinant of survival in advanced pancreatic cancer patients. Common functional variation in this gene might interact with endogenous vitamin D and gemcitabine treatment to determine improved patient survival. These results support evidence for a modulatory role of the vitamin D pathway for the survival of advanced pancreatic cancer patients.

Original languageEnglish (US)
Article numbere0202272
JournalPloS one
Volume13
Issue number8
DOIs
StatePublished - Aug 2018

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'The Vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation'. Together they form a unique fingerprint.

  • Cite this

    Innocenti, F., Owzar, K., Jiang, C., Etheridge, A. S., Gordân, R., Sibley, A. B., Mulkey, F., Niedzwiecki, D., Glubb, D., Neel, N., Talamonti, M. S., Bentrem, D. J., Seiser, E., Yeh, J. J., Van Loon, K., McLeod, H., Ratain, M. J., Kindler, H. L., Venook, A. P., ... McWilliams, R. R. (2018). The Vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PloS one, 13(8), [e0202272]. https://doi.org/10.1371/journal.pone.0202272